Tesamorelin vs Sermorelin
Both Tesamorelin and Sermorelin are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.
Tesamorelin
Evidence ATesamorelin (Egrifta)
An FDA-approved GHRH analog that stimulates natural growth hormone production. Clinically proven to reduce visceral adipose tissue and increasingly used off-label for body recomposition.
View full Tesamorelin profile →Sermorelin
Evidence B+Sermorelin Acetate (GHRH 1-29)
The original synthetic GHRH(1–29) and the most accessible GH-stimulating peptide for age-related hormone decline. Stimulates the body's own pulsatile GH release rather than replacing it.
View full Sermorelin profile →Side-by-Side
| Attribute | Tesamorelin | Sermorelin |
|---|---|---|
| Evidence Grade | A | B+ |
| FDA Status | FDA-approved for HIV-associated lipodystrophy | FDA-approved (1990) for pediatric growth hormone deficiency; off-label adult use via compounding pharmacies |
| Typical Dose | 2 mg daily (subcutaneous) | 200–500 mcg before bed (subcutaneous) |
| Clinics Indexed | 178 | 220 |
| Categories | growth-hormone, fat-loss | growth-hormone, anti-aging |
Key reported benefits — Tesamorelin
- ✓Visceral fat reduction
- ✓Natural GH stimulation
- ✓Cognitive benefit
- ✓Lean mass
Key reported benefits — Sermorelin
- ✓Natural GH release
- ✓Improved sleep
- ✓Lean body mass
- ✓Recovery
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.